Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) EBITDA (2020 - 2025)

NeuroPace (NPCE) has 6 years of EBITDA data on record, last reported at -$1.8 million in Q4 2025.

  • For Q4 2025, EBITDA rose 51.63% year-over-year to -$1.8 million; the TTM value through Dec 2025 reached -$16.3 million, up 32.86%, while the annual FY2025 figure was -$16.3 million, 24.61% up from the prior year.
  • EBITDA reached -$1.8 million in Q4 2025 per NPCE's latest filing, up from -$2.6 million in the prior quarter.
  • Across five years, EBITDA topped out at -$1.8 million in Q4 2025 and bottomed at -$13.2 million in Q2 2022.
  • Average EBITDA over 5 years is -$7.9 million, with a median of -$8.3 million recorded in 2021.
  • Peak YoY movement for EBITDA: plummeted 139.82% in 2021, then skyrocketed 51.63% in 2025.
  • A 5-year view of EBITDA shows it stood at -$11.0 million in 2021, then grew by 0.71% to -$10.9 million in 2022, then skyrocketed by 43.22% to -$6.2 million in 2023, then skyrocketed by 41.08% to -$3.7 million in 2024, then surged by 51.63% to -$1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$1.8 million in Q4 2025, -$2.6 million in Q3 2025, and -$6.8 million in Q2 2025.